£25.4 M

Summit Therapeutics Revenue FY, 2018
Summit Therapeutics Net income (FY, 2018)-7.1 M
Summit Therapeutics EBITDA (FY, 2018)-12.6 M
Summit Therapeutics EBIT (FY, 2018)-12.8 M
Summit Therapeutics Cash, 31-Jan-201820.1 M

Summit Therapeutics Income Statement

Annual

GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

113.0k531.0k1.0m3.0m1.8m189.0k763.0k1.8m1.8m1.8m2.1m1.5m2.3m25.4m

Revenue growth, %

16%(32%)

Cost of goods sold

279.0k233.0k304.0k1.6m1.1m

Gross profit

(166.0k)298.0k730.0k1.4m773.0k

Gross profit Margin, %

(147%)56%71%46%42%

Operating expense total

572.0k(1.4m)5.1m13.2m25.1m5.9m6.7m4.8m6.4m(4.9m)14.9m27.2m38.2m

EBITDA

(10.1m)(19.9m)(5.1m)(5.8m)(2.8m)(3.6m)6.7m(12.7m)(20.3m)(24.8m)(12.6m)

EBITDA margin, %

(334%)(1084%)(2686%)(755%)(159%)(198%)365%(590%)(1399%)(1076%)(49%)

EBIT

(739.0k)1.7m(4.4m)(11.8m)(24.3m)(5.8m)(5.9m)(3.0m)(4.6m)6.7m(12.7m)(20.3m)(24.9m)(12.8m)

EBIT margin, %

(654%)326%(422%)(388%)(1330%)(3048%)(777%)(170%)(252%)364%(592%)(1402%)(1079%)(50%)

Pre tax profit

(523.0k)(1.1m)(3.5m)(11.0m)(24.1m)(5.8m)(5.9m)(3.0m)(4.6m)(6.7m)(12.7m)(23.2m)(25.7m)(10.9m)

Income tax expense

24.0k155.0k489.0k911.0k1.7m(372.0k)1.2m304.0k341.0k607.0k1.3m3.1m4.3m3.8m

Net Income

(499.0k)(995.0k)(3.0m)(10.1m)(22.4m)(6.2m)(4.7m)(2.7m)(4.2m)(6.1m)(11.4m)(20.1m)(21.4m)(7.1m)

Summit Therapeutics Balance Sheet

Annual

GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.2m12.6m18.3m10.1m2.7m6.1m3.3m2.1m3.4m2.0m11.3m16.3m28.1m20.1m

Accounts Receivable

40.0k129.0k283.0k189.0k651.0k41.0k32.0k47.0k51.0k

Inventories

27.0k187.0k337.0k391.0k

Current Assets

14.3m13.2m19.6m12.7m5.4m6.6m3.7m2.6m4.2m3.1m15.2m20.8m33.3m35.9m

PP&E

1.0k1.3m2.6m4.3m3.7m335.0k260.0k149.0k23.0k43.0k55.0k83.0k116.0k809.0k

Goodwill

4.2m4.1m4.1m

Total Assets

14.3m14.5m22.6m34.9m13.9m11.5m5.1m3.9m4.4m7.3m19.4m25.1m37.6m54.0m

Accounts Payable

18.0k488.0k1.2m1.8m675.0k149.0k332.0k372.0k254.0k349.0k1.2m716.0k906.0k4.4m

Current Liabilities

186.0k705.0k1.4m3.4m1.9m1.1m1.2m1.3m1.5m1.9m3.7m3.2m10.9m18.9m

Non-Current Liabilities

691.0k697.0k4.3m3.5m2.1m205.0k205.0k664.0k709.0k5.8m30.2m25.1m

Total Debt

66.0k66.0k188.0k

Total Liabilities

186.0k1.4m2.1m7.7m5.4m3.2m1.4m1.5m1.5m2.5m4.4m9.0m41.1m44.1m

Additional Paid-in Capital

3.1m3.1m3.7m5.0m5.6m6.9m6.9m7.1m8.8m10.1m411.0k613.0k618.0k736.0k

Retained Earnings

(499.0k)(995.0k)(3.0m)(10.1m)(22.4m)(6.2m)(4.7m)(2.7m)(4.2m)(6.1m)(11.4m)(20.1m)(21.4m)(7.1m)

Total Equity

14.1m13.1m20.5m27.2m8.6m8.3m3.7m2.4m2.9m4.8m15.0m16.1m(3.5m)9.9m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1 x1.1 x1.1 x1.3 x1.6 x1.4 x1.4 x1.6 x1.5 x1.5 x1.3 x1.6 x-10.8 x5.5 x

Summit Therapeutics Cash Flow

Annual

GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(499.0k)(995.0k)(3.0m)(10.1m)(22.4m)(6.2m)(4.7m)(2.7m)(4.2m)(6.1m)(11.4m)(20.1m)(21.4m)(7.1m)

Cash From Operating Activities

185.0k1.4m3.2m8.1m(10.1m)(3.1m)(2.7m)(2.4m)(3.2m)(5.9m)(11.3m)(17.2m)12.1m(14.7m)

Cash From Financing Activities

14.1m757.0k9.9m633.0k3.6m5.0m14.0k1.4m4.6m4.5m20.5m22.1m413.0k13.9m

Net Change in Cash

282.0k678.0k2.2m8.2m(7.4m)3.4m(2.8m)(1.2m)1.3m(1.3m)9.2m4.9m12.5m(6.0m)

Income Taxes Paid

607.0k1.3m3.1m

Summit Therapeutics Ratios

GBPY, 2018

Revenue/Employee

577.7k

Financial Leverage

5.5 x
Report incorrect company information

Summit Therapeutics Employee Rating

00 votes
Culture & Values
N/A
Work/Life Balance
N/A
Senior Management
N/A
Salary & Benefits
N/A
Career Opportunities
N/A
Source